Dosing has begun in a Phase 1 clinical trial testing Forma Therapeutics’ investigational therapy FT-7051 in people with metastatic castration-resistant prostate cancer (mCRPC). Recruiting at sites in Arizona and South Carolina, the open-label trial (NCT04575766) is expected to enroll 45 patients who failed to respond to at least one potent anti-androgen treatment. Contact and site information…
Conditions
Conditions
Cytovia, NCI Team Up to Develop CAR NK-cell Therapy for Solid Tumors
Cytovia Therapeutics has entered into a licensing agreement with the National Cancer Institute (NCI) to develop a new “off-the-shelf” immunotherapy for solid tumors. The immunotherapy is based on “natural killer” or NK immune cells, which have been genetically modified to produce a chimeric antigen receptor, or CAR, that targets a specific cancer protein, Cytovia said…
Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China
China’s regulatory agency has approved the start of a Phase 3 clinical trial testing ATG-010 (selinexor), in combination with Velcade (bortezomib) and dexamethasone, in multiple myeloma patients after one to three prior lines of treatment. The trial will include about 150 patients in China with relapsed of refractory multiple myeloma, and randomly assign them to the…
Phase 3 Trial of Therapy for Inflammation, Insulin-sensitivity in Alzheimer’s to Open
NeurMedix has announced it will soon open a pivotal Phase 3 clinical trial of its lead investigational therapy, NE3107, for people with Alzheimer’s disease, following authorization by the U.S. Food and Drug Administration (FDA). The trial (NCT04669028), to be conducted at about 30 clinical U.S. sites, will be looking to recruit up to 316 people with mild to…
‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer
After promising results from patients enrolled to date, Atossa Therapeutics halted an Australian Phase 2 clinical trial evaluating its investigative oral therapy Endoxifen in women newly diagnosed with invasive, estrogen receptor (ER)-positive breast cancer and scheduled for surgery. “It is a welcome event to halt an ongoing clinical trial because the results are so overwhelmingly…
Keytruda-Yervoy Combo of No Benefit in Advanced NSCLC, Trial Data Show
First-line treatment with a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) failed to prolong survival and delay disease progression in patients with advanced non-small cell lung cancer (NSCLC) compared with Keytruda alone, according to data from a Phase 3 trial. The KEYNOTE-598 (NCT03302234) trial involved patients whose tumors produced high levels of PD-L1 and harbored…
Under-the-skin Velcade Found to Work Better in Farydak Triple Combo
Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma than does the therapy’s original into-the-vein version, data show. The triple combination treatment with under-the-skin Velcade also was found to induce longer responses than the…
€15M EU Project Seeks to Improve Personalized Medicine Options
The European Union is providing nearly €15 million ($18.1 million) over five years to improve personalized medicine options for people with drug-resistant high-grade serous ovarian cancer. The DECIDER project, funded by the EU’s Horizon 2020 research and innovation program, will apply artificial intelligence methods to develop new diagnostic tools to identify — earlier and more…
Alzheimer’s Association Webinar Tackles Care Disparities for Blacks in US
Older Blacks in the U.S. are twice as likely to develop Alzheimer’s disease (AD) as whites of a similar age, and they’re less likely to be diagnosed. Such a health disparity is why the Alzheimer’s Association is presenting a webinar on Feb. 18, marking Black History Month. Called “Creating a Path Forward: Reaching Health Equity…
CAR T-cell Therapy Breyanzi Approved for Large B-cell Lymphomas
The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) for treating adults with relapsed or refractory large B-cell lymphoma (LBCL) who have had two or more lines of systemic therapy. The approval covers several types of LBCL: diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising…
FDA Clears Way for Clinical Trial of HDP-101
Heidelberg Pharma has been cleared in the U.S. to begin a clinical trial testing its investigational therapy HDP-101 for the treatment of multiple myeloma. The U.S. Food and Drug Administration (FDA) allowed the start of a Phase 1/2a trial following the submission of an investigational new drug (IND) application. The company expects to enroll the…
New AI Tool May Better Predict Relapse After Surgery
Researchers have developed an artificial intelligence (AI) tool that shows the potential to predict prostate cancer aggressiveness and the likelihood of post-surgery relapse more accurately than standard methods can. Called RadClip, for radiomic-clinicopathologic nomogram, the tool was developed by a team from the Center for Computational Imaging and Personalized Diagnostics (CCIPC) at Case Western Reserve…